United Therapeutics

🇺🇸United States

Country: 🇺🇸United States

Ownership: -

Established: 1996-01-01

Employees: -

Market Cap: $15.5B

Website: http://www.unither.com

Clinical Trials

ADAPT - A Patient Registry of the Real-world Use of Orenitram®

Active, not recruiting

Conditions: Pulmonary Arterial Hypertension

Interventions: Drug: Oral treprostinil

First Posted Date: 2017-02-07

Last Posted Date: 2023-08-04

Lead Sponsor: United Therapeutics

Target Recruit Count: 300

Registration Number: NCT03045029

Locations: 🇺🇸
University of Pittsburgh - Heart and Vascular Medicine Institute, Pittsburgh, Pennsylvania, United States
🇺🇸
University of Southern California - Keck Medical Center, Los Angeles, California, United States
🇺🇸
Saint Vincent Hospital and Health Services, Indianapolis, Indiana, United States

and more 38 locations

Open-label Extension of Oral Treprostinil in Subjects With PH Associated With HFpEF

Phase 3

Terminated

Conditions: Pulmonary Hypertension Associated With HFpEF

Interventions: Drug: Oral treprostinil

First Posted Date: 2017-02-06

Last Posted Date: 2020-10-22

Lead Sponsor: United Therapeutics

Target Recruit Count: 48

Registration Number: NCT03043651

Locations: 🇺🇸
Cleveland Clinic, Cleveland, Ohio, United States
🇺🇸
VA Healthcare System of Greater Los Angeles, Los Angeles, California, United States
🇺🇸
University of Arizona, Tucson, Arizona, United States

and more 79 locations

Oral Treprostinil in Subjects With Pulmonary Hypertension Associated With Heart Failure With Preserved Ejection Fraction

Phase 3

Terminated

Conditions: Heart Failure With Preserved Ejection Fraction
Pulmonary Hypertension

Interventions: Drug: Placebo
Drug: Oral treprostinil

First Posted Date: 2017-01-31

Last Posted Date: 2020-11-10

Lead Sponsor: United Therapeutics

Target Recruit Count: 84

Registration Number: NCT03037580

Locations: 🇺🇸
Medical Faculty Associates, George Washington University, Washington, District of Columbia, United States
🇺🇸
Mayo Clinic - Jacksonville, Jacksonville, Florida, United States
🇺🇸
St. Vincent's Lung, Sleep, and Critical Care Specialists, Jacksonville, Florida, United States

and more 79 locations

Safety of Transition From Selexipag to Remodulin® Then Oral Treprostinil in Symptomatic Adult PAH

Phase 2

Withdrawn

Conditions: Pulmonary Arterial Hypertension

Interventions: Drug: Parenteral Remodulin (treprostinil) injection
Drug: Oral Treprostinil

First Posted Date: 2017-01-10

Last Posted Date: 2017-04-11

Lead Sponsor: United Therapeutics

Registration Number: NCT03016468

Safety and Tolerability of Inhaled Treprostinil in Adult PH Due to COPD

Phase 2

Withdrawn

Conditions: Pulmonary Hypertension
Chronic Obstructive Pulmonary Disease

Interventions: Drug: Inhaled Treprostinil

First Posted Date: 2017-01-06

Last Posted Date: 2017-04-11

Lead Sponsor: United Therapeutics

Registration Number: NCT03012646

Study to Compare Triple Therapy (Oral Treprostinil, Ambrisentan, and Tadalafil) With Dual Therapy (Ambrisentan, Tadalafil, and Placebo) in Subjects With Pulmonary Arterial Hypertension

Phase 3

Withdrawn

Conditions: Pulmonary Arterial Hypertension

Interventions: Drug: Oral Treprostinil
Drug: Placebo

First Posted Date: 2016-12-21

Last Posted Date: 2017-11-01

Lead Sponsor: United Therapeutics

Registration Number: NCT02999906

Safety, Tolerability, Pharmacokinetics and Efficacy of Two Different Rates of Subcutanous Remodulin® Dose Titration in Pulmonary Arterial Hypertension

Phase 4

Withdrawn

Conditions: Pulmonary Arterial Hypertension

Interventions: Drug: Slow Dose Titration Group of Subcutaneous Treprostinil
Drug: Rapid Dose Titration Group of Subcutaneous Treprostinil

First Posted Date: 2016-09-09

Last Posted Date: 2017-05-09

Lead Sponsor: United Therapeutics

Registration Number: NCT02893995

Locations: 🇨🇳
Beijing Chao-Yang Hospital, Beijing, China
🇨🇳
Peking Union Medical College Hospital, Beijing, China
🇨🇳
Fu Wai Hospital, Beijing, China

and more 7 locations

An Open Label Extension Study to Evaluate the Safety of Continued Therapy of Subcutanous Remodulin® in Pulmonary Arterial Hypertension

Phase 4

Withdrawn

Conditions: Pulmonary Arterial Hypertension

Interventions: Drug: Subcutaneous Treprostinil

First Posted Date: 2016-08-29

Last Posted Date: 2017-05-09

Lead Sponsor: United Therapeutics

Registration Number: NCT02882126

Locations: 🇨🇳
Beijing Chao-Yang Hospital, Beijing, China
🇨🇳
Xiangya Hospital Centre South University, Changsha, China
🇨🇳
Fu Wai Hospital, Beijing, China

and more 7 locations

Safety and Tolerability of Rapid Dose Titration of Subcutaneous Remodulin® Therapy in PAH Subjects (RAPID)

Phase 4

Completed

Conditions: Pulmonary Arterial Hypertension

Interventions: Drug: Remodulin

First Posted Date: 2016-07-28

Last Posted Date: 2017-10-17

Lead Sponsor: United Therapeutics

Target Recruit Count: 39

Registration Number: NCT02847260

Post-Marketing Assessment of Immunogenicity and Safety of Unituxin® in High-Risk Neuroblastoma Patients

Terminated

Conditions: Neuroblastoma

Interventions: Drug: Dinutuximab

First Posted Date: 2016-02-26

Last Posted Date: 2019-08-05

Lead Sponsor: United Therapeutics

Target Recruit Count: 13

Registration Number: NCT02693171

Locations: 🇺🇸
University of Chicago, Chicago, Illinois, United States
🇺🇸
Duke University Medical Center, Durham, North Carolina, United States
🇺🇸
Dana Farber Cancer Institute, Boston, Massachusetts, United States

and more 15 locations

© Copyright 2024. All Rights Reserved by MedPath

Home Terms & Conditions Privacy Policy